Log In
Print this Print this

Signature KRAS

  Manage Alerts
Collapse Summary General Information
Company Asuragen Inc.
DescriptionMolecular diagnostic test to detect 12 KRAS mutations
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose KRAS mutations
Regulatory Designation
PartnerTheradiag S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today